TY - JOUR
T1 - As a Novel Prognostic Marker, Cysteine/histidine-rich 1 (CYHR1) is a Therapeutic Target in Patients with Esophageal Squamous Cell Carcinoma
AU - Desaki, Ryosuke
AU - Sawada, Genta
AU - Okumura, Hiroshi
AU - Ikeda, Ryuji
AU - Tanabe, Kan
AU - Komatsu, Hisateru
AU - Mimori, Koshi
AU - Mori, Masaki
AU - Kita, Yoshiaki
AU - Uchikado, Yasuto
AU - Arigami, Takaaki
AU - Uenosono, Yoshikazu
AU - Owaki, Tetsuhiro
AU - Ishigami, Sumiya
AU - Natsugoe, Shoji
N1 - Funding Information:
This study was supported by a Grant-in-Aid for Scientists from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Grant No. 24591954).
Publisher Copyright:
© 2015, Society of Surgical Oncology.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Background: Cysteine/histidine-rich 1 (CYHR1) was first discovered in a yeast two-hybrid screen with murine galectin-3, and no previous reports have described a relationship between the CYHR1 gene and human cancer. The current study evaluated the role and significance of CYHR1 in esophageal cancer. Methods: The human esophageal squamous cell carcinoma (ESCC) cell line TE-8 and the CYHR1 knock-down cell line TE-8/small interfering (si)-CYHR1 were used for in vitro and in vivo assays. For clinical study, ESCC tissues (n = 104) were used. Results: Compared with parental cells, TE-8/si-CYHR1 cells had suppressed proliferation and invasion activities. In the in vivo assay, the tumors from TE-8 cells treated with si-CYHR1 had abrogated tumorigenicity. In the clinical study, the expression of CYHR1 mRNA was associated with lymph node metastasis and stage and shown to be an independent prognostic factor. Conclusions: As the findings show, CYHR1 may represent not only a valuable prognostic marker but also a therapeutic target for ESCC patients.
AB - Background: Cysteine/histidine-rich 1 (CYHR1) was first discovered in a yeast two-hybrid screen with murine galectin-3, and no previous reports have described a relationship between the CYHR1 gene and human cancer. The current study evaluated the role and significance of CYHR1 in esophageal cancer. Methods: The human esophageal squamous cell carcinoma (ESCC) cell line TE-8 and the CYHR1 knock-down cell line TE-8/small interfering (si)-CYHR1 were used for in vitro and in vivo assays. For clinical study, ESCC tissues (n = 104) were used. Results: Compared with parental cells, TE-8/si-CYHR1 cells had suppressed proliferation and invasion activities. In the in vivo assay, the tumors from TE-8 cells treated with si-CYHR1 had abrogated tumorigenicity. In the clinical study, the expression of CYHR1 mRNA was associated with lymph node metastasis and stage and shown to be an independent prognostic factor. Conclusions: As the findings show, CYHR1 may represent not only a valuable prognostic marker but also a therapeutic target for ESCC patients.
UR - http://www.scopus.com/inward/record.url?scp=84949949110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949949110&partnerID=8YFLogxK
U2 - 10.1245/s10434-015-5031-0
DO - 10.1245/s10434-015-5031-0
M3 - Article
C2 - 26676980
AN - SCOPUS:84949949110
SN - 1068-9265
VL - 24
SP - 586
EP - 593
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 2
ER -
